| Also known as |
Levetiracetam |
| Blood pressure |
Generally has no significant effect on blood pressure |
| Chemical name |
(S)-О±-Ethyl-2-oxo-1-pyrrolidineacetamide |
| Dosage (medical) |
Typically starts at 500 mg twice daily, adjustable based on patient response and needs |
| Dosage (sports) |
Not applicable, as it is not used to enhance athletic performance |
| Effects |
Reduces the frequency of seizures |
| Formula |
C8H14N2O2 |
| Half-life |
Approximately 6 to 8 hours |
| Hepatotoxicity |
Low risk |
| Lab Test |
Monitoring levels is not typically required but may be done in specific cases |
| Main action |
Acts on synaptic vesicle protein SV2A, which modulates neurotransmitter release |
| Side effects |
May include dizziness, fatigue, drowsiness, irritability, and coordination difficulties |
| Storage conditions |
Store at room temperature, away from light and moisture |
| Strength |
250 mg |
| Substance class |
Anticonvulsant |
| Trade name |
Keppra |
| Use in sports |
Not recognized for use in sports |
| Water Retention |
Negligible |
| Manufacturer |
Pharmaceutical |
